Illinois News Desk

Delveinsight Business Research LLP

The Influenza A Infections market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Influenza A Infections: An Overview

Influenza A virus is the predominant viral etiology of acute respiratory distress syndrome (ARDS) in adults. Risk factors independently associated with ARDS are age between 36 and 55, pregnancy, and obesity, while protective factors are influenza vaccination and infections with Influenza A (H3N2) or Influenza B viruses.

There are four types of influenza viruses: A, B, C, and D. Human influenza A and B viruses cause seasonal epidemics of disease (known as flu season) almost every winter in the United States. Influenza A viruses are the only viruses known to cause flu pandemics, i.e., global epidemics of flu disease. A pandemic can occur when a new and different influenza A virus infects people and can spread efficiently among people. Influenza C virus infections generally cause mild illness and are not thought to cause human epidemics. Influenza D viruses primarily affect cattle and are not known to infect or cause illness in people.

Influenza A Infections Market Key Facts

• The total market size of Influenza A in the United States is USD 3,623 million in 2021 and is projected to grow during the forecast period (2022-2032).

• In 2021, among all the therapy-wise market size of influenza A, the highest revenue was generated by FLUZONE (High Dose)/FLUBLOK, i.e., ~USD 1164 million, while FLUMIST generated the lowest revenue, i.e., ~USD 29 million in the US.

• Between the prophylaxis market and treatment market, prophylaxis market is expected to capture more share with many potential candidates, including CD388, VXA-A1.1, VIR-2482, mRNA-1010, and others present in the emerging pipeline.

• The total vaccinated pool of Influenza A in the United States was approximately 176 million in 2021.

• The total Influenza A positive cases in the United States comprised 42,580 cases in 2021 and are projected to increase during the study period.

• Many major companies are investing in novel molecule types for the treatment and prevention of influenza A, such as monoclonal antibodies (VIR-2482), polyclonal antibodies (SAB-176), and others, which will boost the influenza A market in the future

Influenza A Infections Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Influenza A Infections market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Influenza A Infections market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Influenza A Infections Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Influenza A Infections Epidemiology, Segmented as –

• Total Treated Cases of Influenza A Infections in the 7MM (2019–2032)

• Strain-specific Cases of Influenza A Infections in the 7MM (2019–2032)

• Incidence of Influenza Infections in the 7MM (2019–2032)

• Incidence of Influenza A Infections in the 7MM (2019–2032)

Influenza A Infections Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Influenza A Infections market or expected to be launched during the study period. The analysis covers the Influenza A Infections market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Influenza A Infections pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Influenza A Infections Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/influenza-a-infections-market

The Key Companies in the Influenza A Infections Therapeutics Market Include:

• Cidara Therapeutics

• SAb Biotherapeutics

• FluGen

• Moderna

• Vir Biotechnology

• Vaxart

And Many Others

Influenza A Infections Emerging and Marketed Drugs Covered in the Report Include: 

• CD388: Cidara Therapeutics

• FLUZONE QUADRIVALENT: Sanofi

• Ingavirin: Valenta Pharm JSC

• RAPIVAB (peramivir injection): BioCryst Pharmaceuticals

• RELENZA (zanamivir): Vaxart/GlaxoSmithKline

• SAB-176: SAb Biotherapeutics

• VIR-2482: Vir Biotechnology

• XOFLUZA (baloxavir marboxil): Genentech/Roche

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

https://www.delveinsight.com/sample-request/influenza-a-infections-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Influenza A Infections Competitive Intelligence Analysis

4. Influenza A Infections Market Overview at a Glance

5. Influenza A Infections Disease Background and Overview

6. Influenza A Infections Patient Journey

7. Influenza A Infections Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Influenza A Infections Treatment Algorithm, Current Treatment, and Medical Practices

9. Influenza A Infections Unmet Needs

10. Key Endpoints of Influenza A Infections Treatment

11. Influenza A Infections Marketed Products

12. Influenza A Infections Emerging Drugs and Latest Therapeutic Advances

13. Influenza A Infections Seven Major Market Analysis

14. Attribute Analysis

15. Influenza A Infections Market Outlook (In US, EU5, and Japan)

16. Influenza A Infections Access and Reimbursement Overview

17. KOL Views on the Influenza A Infections Market

18. Influenza A Infections Market Drivers

19. Influenza A Infections Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/influenza-a-infections-market

Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/